Invesco
ADMA icon

Invesco’s ADMA Biologics ADMA Stock Holding History

Invesco’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.55M Sell
544,021
-3,575,556
-87% -$32.6M ﹤0.01% 2260
2026
Q1 		$37.1M Sell
4,119,577
-7,665,625
-65% -$121M ﹤0.01% 1189
2025
Q4 		$215M Sell
11,785,202
-720,276
-6% -$12.1M 0.02% 652
2025
Q3 		$183M Sell
12,505,478
-312,663
-2% -$5.36M 0.03% 696
2025
Q2 		$233M Sell
12,818,141
-48,763
-0.4% -$994K 0.04% 570
2025
Q1 		$255M Buy
12,866,904
+1,570,649
+14% +$27.2M 0.05% 505
2024
Q4 		$194M Sell
11,296,255
-1,323,514
-10% -$24.9M 0.04% 638
2024
Q3 		$252M Sell
12,619,769
-550,967
-4% -$8.57M 0.05% 511
2024
Q2 		$147M Buy
13,170,736
+5,366,509
+69% +$45M 0.03% 672
2024
Q1 		$51.5M Buy
7,804,227
+1,692,454
+28% +$9.25M 0.01% 1014
2023
Q4 		$27.6M Buy
6,111,773
+694,607
+13% +$2.57M 0.01% 1255
2023
Q3 		$19.4M Buy
5,417,166
+426,446
+9% +$1.64M 0.01% 1356
2023
Q2 		$18.4M Buy
4,990,720
+164,104
+3% +$608K ﹤0.01% 1412
2023
Q1 		$16M Buy
4,826,616
+615,141
+15% +$2.13M ﹤0.01% 1469
2022
Q4 		$16.3M Buy
4,211,475
+785,726
+23% +$2.42M ﹤0.01% 1491
2022
Q3 		$8.32M Buy
3,425,749
+3,109,896
+985% +$7.46M ﹤0.01% 1918
2022
Q2 		$625K Sell
315,853
-113,610
-26% -$224K ﹤0.01% 3225
2022
Q1 		$786K Sell
429,463
-130,463
-23% -$204K ﹤0.01% 3187
2021
Q4 		$789K Buy
+559,926
New +$736K ﹤0.01% 3189
2021
Q2 		– Sell
-17,896
Closed -$31K – 3958
2021
Q1 		$31K Buy
17,896
+3,602
+25% +$8.24K ﹤0.01% 3845
2020
Q4 		$28K Buy
+14,294
New +$30K ﹤0.01% 3756
2019
Q4 		– Sell
-162,632
Closed -$724K – 3648
2019
Q3 		$724K Buy
+162,632
New +$680K ﹤0.01% 3132
2019
Q2 		– Sell
-54,729
Closed -$207K – 3712
2019
Q1 		$207K Buy
54,729
+4,422
+9% +$15.6K ﹤0.01% 3615
2018
Q4 		$120K Sell
50,307
-11,099
-18% -$55K ﹤0.01% 3624
2018
Q3 		$381K Buy
61,406
+15,133
+33% +$87.1K ﹤0.01% 3537
2018
Q2 		$209K Buy
+46,273
New +$231K ﹤0.01% 3693

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Invesco's ADMA Position: Q2 2026 in Review

Invesco reduced its ADMA Biologics (ADMA) stake by 87% in Q2 2026, selling an estimated $32.6M and leaving 544,021 shares worth $4.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2260.

Invesco first reported a position in ADMA in Q2 2018 and has held it in 26 quarters since. The position peaked at $255M in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Invesco held 544,021 shares of ADMA Biologics worth $4.55M as of Q2 2026.
  • Invesco sold 3,575,556 ADMA Biologics shares in Q2 2026, an estimated $32.6M.
  • ADMA Biologics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2260 holding.
  • Invesco first reported a position in ADMA Biologics in Q2 2018 and has held it in 26 quarters since.
  • Invesco's ADMA Biologics position peaked at $255M in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.